Icosavax, Inc.

If you purchased Icosavax, Inc. securities and would like to join the action, please click "Join This Action" below.

We would handle the action on a contingent fee basis, whereby you would not be responsible for out of pocket payment of our legal fees or expenses.

ICVX STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF ICOSAVAX, INC. IS FAIR TO SHAREHOLDERS

 

December 12, 2023.

 

New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones, is fair to Icosavax shareholders.

 

The investigation concerns whether Icosavax and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Icosavax shareholders; (2) determine whether AstraZeneca is underpaying for Icosavax; and (3) disclose all material information necessary for Icosavax shareholders to adequately assess and value the merger consideration. On behalf of Icosavax shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

 

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

 

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Signed pursuant to California Civil Code Section 1633.1, et seq., and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: February 27, 2024